⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 8, 2025

Table S4 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Zahra Davoudi Thomas S. Dexheimer Nathan P. Coussens Thomas Silvers Raymond G. Fox Samantha B. Kemp Poorva Juneja Joel Morris Melinda G. Hollingshead Naoko Takebe James H. Doroshow Beverly A. Teicher

View Full Paper

Ask AI

Bookmark

Share

Key Points

Ras pathway inhibitors combined with targeted agents reduced tumor growth in patient-derived spheroids with oncogenic kras variants.
Analysis highlights the importance of variant status of signaling proteins in patient-derived cancer cell lines.
This research involved patient-derived spheroids as a model to assess cancer treatment effectiveness on various oncogenic kras variants.
Findings suggest potential for tailored therapeutic approaches targeting specific signaling protein variants in cancer treatment.

Implication

Analysis shows effectiveness of ras pathway inhibitors and targeted agents in patient-derived spheroids, implying new treatment strategies.

Abstract

Table S4. The variant status of key signaling proteins from the NCI PDMR patient-derived cancer cell lines.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davoudi et al. (2025) studied this question.

synapsesocial.com/papers/68e861857ef2f04ca37e3ba0 https://doi.org/10.1158/2767-9764.30304660

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S2 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
2Table S1 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
3Figure S17 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
4Table S3 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025
5Supplementary Materials & Methods from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types2025